Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, Год журнала: 2024, Номер unknown

Опубликована: Май 27, 2024

Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started clinical first ICI, ipilimumab, in 2011. Since then, field ICI therapy has rapidly expanded — FDA approval 10 different drugs so far and their incorporation into therapeutic regimens a range malignancies. While ICIs have shown high anti‐cancer efficacy, they also characteristic side effects, termed immune‐related adverse events (irAEs). These effects hinder potential and, therefore, finding ways to prevent treat them is paramount importance. current protocols manage irAEs follow an empirical route steroid administration more severe cases, withdrawal. However, this approach not optimal many as there are often steroid‐refractory irAEs, for corticosteroid promote tumour progression. This review surveys alternative approaches treatments goal summarizing highlighting best attempts without compromising anti‐tumour immunity allowing rechallenge after resolution irAEs.

Язык: Английский

---

Fever of unknown origin associated with immune checkpoint inhibitors

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Март 12, 2024

Since the approval for treatment of melanoma in 2014, immune checkpoint inhibitors (ICIs) have revolutionized therapy pattern across various malignancies. Coinciding with their frequent usage, adverse effects, including fever, cannot be neglected. In context cancer diseases and treatments, fever unknown origin (FUO), which has long posed a challenge clinicians terms diagnosis management, brings forth new connotation significance. this paper review, we present concept ICIs-associated FUO, consider activated system elevated cytokines as common mechanisms by ICIs induce immune-related events (irAEs), summarize compare primary etiologies ICI-associated it conventional types FUO.

Язык: Английский

---

Galectin 7 leads to a relative reduction in CD4+ T cells, mediated by PD-1

Scientific Reports, Год журнала: 2024, Номер 14(1)

Опубликована: Март 19, 2024

Abstract The role of glycan-binding proteins as an activator immune regulatory receptors has gained attention recently. We report that galectin 7 reduced CD4+ T cell percentage in both vitro culture and mouse tumor models. Immunohistochemical staining esophageal cancer patient samples showed a lower cells the high area. lack depletion by PD-1 knockout mice supports mediating effects 7. binding assays demonstrate binds to N -glycosylation on N74 N116 sites leads recruitment SHP-2. NFAT suppressive activity was abrogated upon overexpression dominant negative SHP-2 mutant or inhibition siRNA. Glycosylation been reported play critical surface expression, stability, interaction with its ligand PD-L1. This further expands significance glycosylation suggests 7, protein, interacts receptor through recognition.

Язык: Английский

---

Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor

International Journal of Cancer, Год журнала: 2024, Номер 155(2), С. 193 - 202

Опубликована: Март 30, 2024

Tissue-resident memory T cells (TRM) are a specialized subset of that reside in tissues and provide long-term protective immunity against pathogens enter the body through specific tissue. TRM have phenotype preferentially barrier tissues. Recent studies revealed main target immune checkpoint inhibitor immunotherapy since their role cancer immunosurveillance. Furthermore, also play crucial part pathogenesis immune-related adverse events (irAEs). Here, we concise review biological characteristics cells, major advances recent findings regarding involvement corresponding irAEs.

Язык: Английский

---

Increased incidence of co-trimoxazole-induced rash in patients on systemic corticosteroid treatment for toxicity associated with immune checkpoint inhibitors

British Journal of Dermatology, Год журнала: 2024, Номер 191(3), С. 465 - 467

Опубликована: Май 16, 2024

Our cross-sectional study demonstrates that there is a high rate of co-trimoxazole-induced drug rash in patients treated for immune-related adverse events, with those developing appearing to have reduced survival.

Язык: Английский

---